Telomere length regulators are activated in young men after pediatric kidney transplantation compared to healthy controls and survivors of childhood cancer—A cross-sectional study
Corresponding Author
Kira Endén
Department of Pediatric Nephrology and Transplantation, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Department of Pediatrics, Tampere University Hospital, Tampere, Finland
Correspondence
Kira Endén, Children's Hospital, PO BOX 281, Helsinki 00029 HUS, Finland.
Email: [email protected]
Search for more papers by this authorJuuso Tainio
Department of Pediatric Nephrology and Transplantation, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Search for more papers by this authorMi Hou
Department of Women's and Children's Health, NORDFERTIL Research Lab, Karolinska Institute and University Hospital, Stockholm, Sweden
Search for more papers by this authorAnu Suominen
Division of Hematology-Oncology and Stem Cell Transplantation, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Search for more papers by this authorMikko Pakarinen
Pediatric Liver and Gut Research Group and Section of Pediatric Surgery, Children's Hospital, Helsinki University Hospital, Helsinki, Finland
Search for more papers by this authorTao Huang
School of Medicine, Shandong University, Jihan, China
Search for more papers by this authorOlle Söder
Department of Women's and Children's Health, NORDFERTIL Research Lab, Karolinska Institute and University Hospital, Stockholm, Sweden
Search for more papers by this authorHannu Jalanko
Department of Pediatric Nephrology and Transplantation, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Search for more papers by this authorKirsi Jahnukainen
Department of Women's and Children's Health, NORDFERTIL Research Lab, Karolinska Institute and University Hospital, Stockholm, Sweden
Division of Hematology-Oncology and Stem Cell Transplantation, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Search for more papers by this authorTimo Jahnukainen
Department of Pediatric Nephrology and Transplantation, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Search for more papers by this authorCorresponding Author
Kira Endén
Department of Pediatric Nephrology and Transplantation, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Department of Pediatrics, Tampere University Hospital, Tampere, Finland
Correspondence
Kira Endén, Children's Hospital, PO BOX 281, Helsinki 00029 HUS, Finland.
Email: [email protected]
Search for more papers by this authorJuuso Tainio
Department of Pediatric Nephrology and Transplantation, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Search for more papers by this authorMi Hou
Department of Women's and Children's Health, NORDFERTIL Research Lab, Karolinska Institute and University Hospital, Stockholm, Sweden
Search for more papers by this authorAnu Suominen
Division of Hematology-Oncology and Stem Cell Transplantation, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Search for more papers by this authorMikko Pakarinen
Pediatric Liver and Gut Research Group and Section of Pediatric Surgery, Children's Hospital, Helsinki University Hospital, Helsinki, Finland
Search for more papers by this authorTao Huang
School of Medicine, Shandong University, Jihan, China
Search for more papers by this authorOlle Söder
Department of Women's and Children's Health, NORDFERTIL Research Lab, Karolinska Institute and University Hospital, Stockholm, Sweden
Search for more papers by this authorHannu Jalanko
Department of Pediatric Nephrology and Transplantation, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Search for more papers by this authorKirsi Jahnukainen
Department of Women's and Children's Health, NORDFERTIL Research Lab, Karolinska Institute and University Hospital, Stockholm, Sweden
Division of Hematology-Oncology and Stem Cell Transplantation, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Search for more papers by this authorTimo Jahnukainen
Department of Pediatric Nephrology and Transplantation, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Search for more papers by this authorAbstract
Chronic diseases are known to cause premature aging and frailty. Data about telomere length and telomere length-regulating proteins after pediatric KTx are scarce. Leukocyte telomere length and gene expression level of eight telomere-binding proteins were analyzed in 20 KTx recipients, eight childhood NBL survivors, and nine healthy controls. The influence of key clinical parameters on telomere length and on regulators of telomere length was evaluated. The telomere length in the KTx recipients tended to be shorter (0.53 AU) than in the healthy controls (0.64 AU) but longer than in the NBL survivors (0.38 AU). There was no significant difference in telomere length between the NBL survivors and the KTx recipients (P = .110). The gene expression level of telomere length-preserving protein RPA1 was significantly higher in the KTx recipients than among the NBL survivors or healthy controls, while the expression of TRF2 and the tumor suppressor gene p16 was significantly higher in the KTX recipients when compared to the controls. TRF2 and TIN2 correlated significantly with hsCRP; additionally, TRF2 showed significant correlation with plasma creatinine and eGFR. KTx recipients have near to normal telomere length, but they have significantly higher gene expression levels of telomere regulatory proteins compared with healthy controls, suggesting activation of mechanisms preserving telomere length among KTx recipients. Our results suggest that declined graft function and consequent inflammatory response may have influence on telomerase activity.
REFERENCES
- 1Jahnukainen T, Bjerre A, Larsson M, et al. The second report of the Nordic Pediatric Renal Transplantation Registry 1997–2012: more infant recipients and improved graft survivals. Pediatr Transplant. 2016; 20(3): 364-371.
- 2Tainio J, Jahnukainen K, Nurmio M, Pakarinen M, Jalanko H, Jahnukainen T. Testicular function, semen quality, and fertility in young men after renal transplantation during childhood or adolescence. Transplantation. 2014; 98(9): 987-993.
- 3Tainio J, Qvist E, Holtta T, Pakarinen M, Jahnukainen T, Jalanko H. Metabolic risk factors and long-term graft function after paediatric renal transplantation. Transpl Int. 2014; 27(6): 583-592.
- 4Haavisto A, Korkman M, Holmberg C, Jalanko H, Qvist E. Neuropsychological profile of children with kidney transplants. Nephrol Dial Transplant. 2012; 27(6): 2594-2601.
- 5Vatanen A, Hou M, Huang T, et al. Clinical and biological markers of premature aging after autologous SCT in childhood cancer. Bone Marrow Transplant. 2017; 52: 600.
- 6Saliha R, Syed Tasleem R, Farzana M. Telomere length variations in aging and age-related diseases. Curr Aging Sci. 2014; 7(3): 161-167.
- 7Steenstrup T, Hjelmborg J, Mortensen LH, Kimura M, Christensen K, Aviv A. Leukocyte telomere dynamics in the elderly. Eur J Epidemiol. 2013; 28(2): 181-187.
- 8Willeit P, Raschenberger J, Heydon EE, et al. Leucocyte telomere length and risk of type 2 diabetes mellitus: new prospective cohort study and literature-based meta-analysis. PLoS ONE. 2014; 9(11): e112483.
- 9Strandberg TE, Saijonmaa O, Tilvis RS, et al. Association of telomere length in older men with mortality and midlife body mass index and smoking. J Gerontol A Biol Sci Med Sci. 2011; 66(7): 815-820.
- 10Sanders JL, Newman AB. Telomere length in epidemiology: a biomarker of aging, age-related disease, both, or neither? Epidemiol Rev. 2013; 35: 112-131.
- 11Rode L, Nordestgaard BG, Weischer M, Bojesen SE. Increased body mass index, elevated C-reactive protein, and short telomere length. J Clin Endocrinol Metab. 2014; 99(9): E1671-E1675.
- 12Jackowska M, Carvalho LA. Short sleep duration is associated with short telomere length in healthy men; findings from Whitehall II cohort study. PLoS ONE. 2012; 7(10): e47292.
- 13Brouilette SW, Whittaker A, Stevens SE, van der Harst P, Goodall AH, Samani NJ. Telomere length is shorter in healthy offspring of subjects with coronary artery disease: support for the telomere hypothesis. Heart. 2008; 94(4): 422-425.
- 14Dei Cas A, Spigoni V, Franzini L, et al. Lower endothelial progenitor cell number, family history of cardiovascular disease and reduced HDL-cholesterol levels are associated with shorter leukocyte telomere length in healthy young adults. Nutr Metab Cardiovasc Dis. 2013; 23(3): 272-278.
- 15Shen Q, Zhao X, Yu L, et al. Association of leukocyte telomere length with type 2 diabetes in mainland Chinese populations. J Clin Endocrinol Metab. 2012; 97(4): 1371-1374.
- 16Meijers RW, Litjens NH, de Wit EA, Langerak AW, Baan CC, Betjes MG. Uremia-associated immunological aging is stably imprinted in the T-cell system and not reversed by kidney transplantation. Transpl Int. 2014; 27(12): 1272-1284.
- 17Crepin T, Carron C, Roubiou C, et al. ATG-induced accelerated immune senescence: clinical implications in renal transplant recipients. Am J Transplant. 2015; 15(4): 1028-1038.
- 18Luttropp K, Nordfors L, McGuinness D, et al. Increased telomere attrition after renal transplantation-impact of antimetabolite therapy. Transpl Direct. 2016; 2(12): e116.
- 19Vatanen A, Hou M, Huang T, et al. Clinical and biological markers of premature aging after autologous SCT in childhood cancer. Bone Marrow Transpl. 2017; 52(4): 600-605.
- 20Kooman JP, Dekker MJ, Usvyat LA, et al. Inflammation and premature aging in advanced chronic kidney disease. Am J Physiol Renal Physiol. 2017; 313(4): F938-F950.
- 21Li P, Tian C, Ge N, et al. Premature senescence of T cells in long-term survivors of renal transplantation. Biochem Biophys Res Commun. 2011; 407(3): 599-604.
- 22Frescas D, de Lange T. TRF2-tethered TIN2 can mediate telomere protection by TPP1/POT1. Mol Cell Biol. 2014; 34(7): 1349-1362.
- 23Gramatges MM, Short B. Telomeres: from dyskeratosis congenita to sporadic aplastic anemia and malignancy. Transl Res. 2013; 162(6): 353-363.
- 24Chatterjee S. Telomeres in health and disease. J Oral Maxillofacial Pathol: JOMFP. 2017; 21(1): 87-91.
- 25van Steensel B, Smogorzewska A, de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell. 1998; 92(3): 401-413.
- 26Smogorzewska A, van Steensel B, Bianchi A, et al. Control of human telomere length by TRF1 and TRF2. Mol Cell Biol. 2000; 20(5): 1659-1668.
- 27Chebel A, Catallo R, Mabon C, et al. Rapamycin safeguards lymphocytes from DNA damage accumulation in vivo. Eur J Cell Biol. 2016; 95(9): 331-341.
- 28Da-Silva N, Arasaradnam R, Getliffe K, Sung E, Oo Y, Nwokolo C. Altered mRNA expression of telomere binding proteins (TPP1, POT1, RAP1, TRF1 and TRF2) in ulcerative colitis and Crohn's disease. Dig Liver Dis. 2010; 42(8): 544-548.
- 29Carrero JJ, Stenvinkel P, Fellström B, et al. Telomere attrition is associated with inflammation, low fetuin-A levels and high mortality in prevalent haemodialysis patients. J Intern Med. 2008; 263(3): 302-312.
- 30Stefanidis I, Voliotis G, Papanikolaou V, et al. Telomere length in peripheral blood mononuclear cells of patients on chronic hemodialysis is related with telomerase activity and treatment duration. Artif Organs. 2015; 39(9): 756-764.
- 31Tsirpanlis G, Chatzipanagiotou S, Boufidou F, et al. Telomerase activity is decreased in peripheral blood mononuclear cells of hemodialysis patients. Am J Nephrol. 2006; 26(1): 91-96.
- 32Endén K, Tainio J, Jalanko H, Jahnukainen K, Jahnukainen T. Lower quality of life in young men after pediatric kidney transplantation when compared to healthy controls and survivors of childhood leukemia—a cross-sectional study. Transpl Int. 2018; 31(2): 157-164.
- 33Lee JJ, Kook H, Chung IJ, et al. Telomere length changes in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transpl. 1999; 24(4): 411-415.
- 34Oetting WS, Guan W, Schladt DP, et al. Telomere length of recipients and living kidney donors and chronic graft dysfunction in kidney transplants. Transplantation. 2013; 97(3): 325-329.
- 35Lai T-P, Wright WE, Shay JW. Comparison of telomere length measurement methods. Philos Trans R Soc Lond B Biol Sci. 2018; 373(1741): 20160451.
Citing Literature
